iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
Marketwire - Thu Mar 27, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
Marketwire - Tue Mar 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the 26th Annual ROTH Conference being held March 10-12, 2014 at the Ritz Carlton in Dana Point, California.
PlayStation®4 (PS4(TM)) Sales Surpass 6.0 Million Units Worldwide In Less Than 4 Months Since Launch, Rapidly Popularizes A New Way To Enjoy Social Interaction Through Gaming
PR Newswire - Tue Mar 04, 1:18AM CST
Sony Computer Entertainment Inc. (SCE) today announced that the PlayStation®4 (PS4(TM)) computer entertainment system has cumulatively sold through more than 6.0 million units*1 globally as of March 2, 2014 (JST). This also includes the 370,000 units sold through in Japan since its launch on February 22.
iBio enters Phase 1 clinical trial of malaria vaccine candidate
M2 - Tue Feb 11, 6:42AM CST
US-based plant biotechnology company iBio Inc (NYSE MKT:IBIO) announced on Monday the start of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The candidate is based on its proprietary iBioLaunch platform from the Fraunhofer USA Center for Molecular Biotechnology.
Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
Marketwire - Mon Feb 10, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch(TM) platform by the Fraunhofer USA Center for Molecular Biotechnology.
Trypanosomiasis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2pfn6/trypanosomiasis) has announced the addition of the "Trypanosomiasis - Pipeline Review, H2 2013" report to their offering. 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. Scope - A snapshot of the global therapeutic scenario for Trypanosomiasis. - A review of the Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Trypanosomiasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Trypanosomiasis Overview Therapeutics Development Pipeline Products for Trypanosomiasis - Overview Pipeline Products for Trypanosomiasis - Comparative Analysis Trypanosomiasis - Therapeutics under Development by Companies Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes Trypanosomiasis - Pipeline Products Glance Early Stage Products Trypanosomiasis - Products under Development by Companies Trypanosomiasis - Products under Investigation by Universities/Institutes Trypanosomiasis - Companies Involved in Therapeutics Development Trypanosomiasis - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Subunit Vaccine For Trypanosomiasis - Drug Profile Xenomycin - Drug Profile Cysteine Proteases Inhibitors - Drug Profile Drug For Parasitic Diseases - Drug Profile Nitrobenzyl Phosphoramide Mustards - Drug Profile Trypanosomiasis - Recent Pipeline Updates Companies Mentioned iBio, Inc. Panacela Labs, Inc. For more information visit http://www.researchandmarkets.com/research/n2...nosomiasis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
Marketwire - Thu Jan 30, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biopharmaceutical products, has added a proprietary biotherapeutic product for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis to its product pipeline.
Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013 Research Report
M2 - Thu Jan 23, 8:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/jj5jz9/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013" report to their offering. 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. Scope - A snapshot of the global therapeutic scenario for Alpha- Antitrypsin Deficiency. - A review of the Alpha- Antitrypsin Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Alpha- Antitrypsin Deficiency pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sangamo BioSciences, Inc. Grifols, S.A. rEVO Biologics Alnylam Pharmaceuticals, Inc. Protalix BioTherapeutics, Inc. Kamada Ltd. Applied Genetic Technologies Corporation Intrexon Corporation Polyphor Ltd. iBio, Inc. Amunix, Inc. OrphageniX, Inc. Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/jj5jz9/alpha About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio Inc wins patent for HPV-related cancer vaccine in China
M2 - Wed Jan 22, 5:35AM CST
US-based plant biotechnology company iBio Inc (NYSE MKT:IBIO) reported on Tuesday that it received a notice of allowance for its patent application "HPV Antigens, Vaccine Compositions, and Related Methods" in China.
iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China
Marketwire - Tue Jan 21, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has received a notice of allowance from the State Intellectual Property Office of the People's Republic of China for its patent application, "HPV Antigens, Vaccine Compositions, and Related Methods."
Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
Marketwire - Wed Jan 15, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer treatment as the first product target for advancement on the iBioLaunch(TM) platform under the License and Collaboration Agreement between the company and Caliber dated February 14, 2013.
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
PR Newswire - Wed Dec 11, 6:00AM CST
Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Douglas J. Beck C.P.A. joined the company as its Chief Financial Officer where he will manage all financial operations. Mr. Beck has a solid financial, accounting and audit expertise and he serves on the SEC Practice Committee and the Chief Financial Officers Committee for the New York State Society of CPAs. He also has significant prior experience in public accounting including at both Andersen LLP and Eisner Amper LLP.
Market Research: Hereditary Angioedema (HAE) - Pipeline Review, H2 2013
M2 - Tue Dec 10, 2:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/x8rgxd/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2013" report to their offering. 'Hereditary Angioedema (HAE) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE). Scope - A snapshot of the global therapeutic scenario for Hereditary Angioedema (HAE). - A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Isis Pharmaceuticals, Inc. Pharming Group N.V. Dyax Corp. ViroPharma Incorporated BioCryst Pharmaceuticals, Inc. CSL Limited iBio, Inc. For more information visit http://www.researchandmarkets.com/research/x8rgxd/hereditary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Fabry Disease Market Report 2013
M2 - Mon Dec 09, 6:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/bprc3p/fabry_disease) has announced the addition of the "Global Fabry Disease Market Report 2013" report to their offering. This report provides information on the therapeutic development for Fabry Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fabry Disease. The analysis is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Fabry Disease. - A review of the Fabry Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fabry Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fabry Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Table of Contents List of Tables List of Figures Introduction REPORT COVERAGE Fabry Disease Overview Therapeutics Development Companies Involved in Fabry Disease Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Amicus Therapeutics, Inc. - Bio Sidus S.A. - Genzyme Corporation - GlaxoSmithKline plc - Green Cross Corporation - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Protalix BioTherapeutics, Inc. - Sanofi-Aventis - greenovation Biotech GmbH - iBio, Inc. For more information visit http://www.researchandmarkets.com/research/bp...ry_disease
iBio Inc announces new senior management team for iBio Brazil
M2 - Wed Nov 06, 5:19AM CST
Protein therapeutics company iBio Inc (NYSE MKT:IBIO) stated on Tuesday the addition of Carlos Picosse as its chief executive officer and Dr. Renato Lobo as its chief medical officer.
iBio Appoints Senior Management for New Business Unit, iBio Brazil
Marketwire - Tue Nov 05, 2:00PM CST
iBio, Inc. (NYSE MKT: IBIO), has appointed Carlos Picosse as chief executive officer and Dr. Renato Lobo as chief medical officer of iBio Brazil, a subsidiary the company is forming to manage and expand iBio's business activities in Brazil.
iBio Resolves NYSE MKT Listing Standards Deficiency
PR Newswire - Mon Oct 28, 7:10AM CDT
iBio, Inc. ( NYSE MKT: IBIO ) today announced receipt on October 25, 2013 of notice from NYSE Regulation that iBio had resolved all previously cited continued listing deficiency with respect to listing standards of the NYSE MKT LLC's (the "Exchange"